Novoeight

Manufactured by Novo Nordisk

Sourced in United States

NovoEight is a laboratory equipment product manufactured by Novo Nordisk. It is designed for use in research and diagnostic settings. The core function of NovoEight is to perform specific laboratory tests and analyses. No further details can be provided in an unbiased and factual manner without extrapolation.

Automatically generated - may contain errors

Lab products found in correlation

Refacto af, by Pfizer (1 mentions) Kogenate fs, by Bayer (1 mentions) Novoseven, by Novo Nordisk (1 mentions) Rvv x, by Prolytix (1 mentions) Recombinant hirudin, by Hyphen Biomed (1 mentions) α thrombin, by Prolytix (1 mentions) Prothrombin, by Prolytix (1 mentions) Fviia, by Prolytix (1 mentions)

4 protocols using novoeight

Comparative Analysis of FVIII Concentrates

Check if the same lab product or an alternative is used in the 5 most similar protocols

A single intravenous dose of 50 IU kg⁻¹ FVIII concentrate was administered to each patient. Patients received the following recombinant FVIII concentrates (Kogenate FS: Bayer, Berkeley, Ca, USA; Advate: Baxter Bioscience, Thousand Oaks, CA, USA; Refacto AF: Pfizer, New York, NY USA; NovoEight: Novo Nordisk, Bagsværd, Denmark) or plasma‐derived FVIII concentrates (Aafact: Blood Transfusion council of the Netherlands Red Cross, Amsterdam, the Netherlands). In general, 3 FVIII level measurements were obtained at 4, 24 and 48 hours after FVIII bolus administration. In a minority of patients, a preinfusion FVIII level was also measured. The need for a washout period and baseline measurement was avoided by collecting time of dosing and doses of 3 previous FVIII concentrate infusions. FVIII plasma levels were measured locally in each treatment centre, using a 1‐stage clotting assay.

van Moort I., Preijers T., Hazendonk H.C., Schutgens R.E., Laros‐van Gorkom B.A., Nieuwenhuizen L., van der Meer F.J., Fijnvandraat K., Leebeek F.W., Meijer K., Mathôt R.A, & Cnossen M.H. (2020). Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 87(6), 2602-2613.

+ Open protocol

+ Expand

Congenital Severe Hemophilia A Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients were eligible for inclusion if they were as follows: male, age < 6 years, diagnosed with congenital severe haemophilia A (FVIII level ≤ 1% at the time of diagnosis), had no previous use of purified clotting FVIII products, including commercially available NovoEight^® (Novo Nordisk); previous exposure of ≤ 5 EDs to blood components, for example cryoprecipitate, fresh frozen plasma (FFP), was accepted.

Yaish H., Matsushita T., Belhani M., Jiménez‐Yuste V., Kavakli K., Korsholm L., Matytsina I., Philipp C., Reichwald K, & Wu R. (2019). Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial. Haemophilia, 26(1), 64-72.

+ Open protocol

+ Expand

Concizumab and Hemostatic Agents Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Concizumab (Novo Nordisk) was added to a HA plasma pool (George King Bio‐Medical Inc.) either alone or in combination with rFVIIa (NovoSeven^®, Novo Nordisk), APCC (FEIBA^®, Takeda) or rFVIII (NovoEight^®, Novo Nordisk).

Kjalke M., Kjelgaard‐Hansen M., Andersen S, & Hilden I. (2021). Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. Journal of Thrombosis and Haemostasis, 19(7), 1687-1696.

+ Open protocol

+ Expand

Coagulation Factor Variant Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

The proteins hFX-R15Q and hFXa-S195A were gifted by Dr. Camire (Children's Hospital of Philadelphia, Philadelphia, United States). TFPI was a gift from Dr. van't Veer (Amsterdam University Medical Centers, Amsterdam, the Netherlands). The human plasma-derived coagulation proteins FVIIa, FIXa, factor XIa (FXIa), prothrombin, α-thrombin, antithrombin, and RVV-X were from Haematologic Technologies. NovoEight was from Novo Nordisk (Plainsboro, New Jersey, United States). Human TF (Innovin) was from Siemens (Newark, New York, United States), and recombinant hirudin was from Hyphen Biomed (Neuville-sur-Oise, France). Recombinant wild-type hFX and venom-derived P. textilis FX and FXa (v-ptFX and v-ptFXa) were prepared, purified, and characterized as described. 15 Recombinant constitutively active B-domainless human factor V (FV-810; hFV) and venomderived P. textilis FV (v-ptFV) were prepared, purified, and characterized as described. 12, 16 The extinction coefficients (E 0.1%, 280 nm ) of the newly generated hFX-ptAP and ptFX-hAP variants were assumed to be similar to hFX and v-ptFX (1.16). 16, 17 The molecular weights of the various proteins used were taken as follows: hFX 58.0 kDa; hFX-ptAP 55.0 kDa; v-ptFX 55.0 kDa; ptFX-hAP 58.0 kDa.

Schreuder M., Poenou G., Strijbis V.J.F., Cheung K.L., Reitsma P.H, & Bos M.H.A. (2020). Evolutionary Adaptations in Pseudonaja Textilis Venom Factor X Induce Zymogen Activity and Resistance to the Intrinsic Tenase Complex. Thrombosis and haemostasis, 120(11).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!